Molecular chaperones, both endoplasmic reticulum and cytosol derived, have been identified as tumor rejection antigens; in animal models, they can elicit prophylactic and therapeutic immune responses against their tumor of origin. Chaperone immunogenic activity derives from three principal characteristics: they bind an array of immunogenic (poly)peptides, they can be efficiently internalized by professional antigen-presenting cells, and once internalized, they traffic to a subcellular compartment(s) where peptide release can occur. Within the antigen-presenting cell, chaperone-derived peptides can be assembled onto major histocompatibility class I molecules for presentation at the antigen-presenting cell surface, thereby yielding the requisite and specific CD8 π T-cell responses that contribute to the process of tumor rejection. Though it is clear that chaperones, in particular GRP94 (gp96), calreticulin and Hsp70, can elicit cellular immune responses, the subcellular basis of chaperone processing by antigen-presenting cells remains mysterious. In this review, we discuss recent reports describing the identification of a chaperone internalization receptor and the physiological release of chaperones from necrotic cells, and we present views on the trafficking pathways within antigen-presenting cells that may function to deliver the chaperone-associated peptides to subcellular organelles for their subsequent exchange onto major histocompatibility complex molecules.
ing interest in the medical and basic sciences communities. Originally discovered in an immunological screen for subcellular components that would elicit prophylactic antitumor immune responses, heat shock proteins have proven efficacious in both prophylactic and therapeutic cancer immunotherapy models (1) (2) (3) (4) (5) (6) . Proteins demonstrated to display this activity include the cytosolic heat shock proteins Hsp90 and Hsp70 and the endoplasmic reticulum (ER) chaperones GRP94 (identical to gp96) and calreticulin (2, 3, 5, 7, 8) . In an effort to clarify terminology, it should be noted that Hsp90 and Hsp70 transcription is up-regulated in response to heat shock, and thus these proteins are by definition heat shock proteins. In contrast, the transcriptional induction of GRP94 and calreticulin occurs in response to nutrient/oxygen deprivation and the accumulation of unfolded proteins in the ER (9), but not heat shock, and thus the immunogenic ER proteins are referred to as molecular chaperones. Hsp90, GRP94, Hsp70 and calreticulin share in common (poly)peptide binding activity, and it is this trait that provides the mechanistic basis for tissue-specific antigenicity. Thus, chaperones can form stable complexes with (poly)peptide substrates and can then be processed by professional antigen presenting cells (APCs) to elicit cellular immune responses. This processing pathway, in overview, is comprised of APC receptor recognition of the chaperone/ (poly)peptide complex, internalization, and a subcellular trafficking/processing pathway that yields the re-presentation of chaperone-associated antigens on APC major histocompatibility complex (MHC) class I molecules (1, (10) (11) (12) (13) .
The re-presentation of chaperone-associated peptides on class I molecules represents an archetype of a process referred to as cross-presentation or cross-priming. Crosspresentation is unique to antigen-presenting cells and encompasses a complex array of trafficking events, whereby extracellular (poly)peptides are internalized, proteolytically processed, and the derived peptides are assembled onto APC class I molecules for presentation on the APC cell surface [reviewed in (14) ]. The significance of this process extends from an immunological division of labor; in general, the class I antigen-processing pathway is devoted to the processing and presentation of intracellular antigens, and the class II antigen-processing pathway to extracellular antigens. For the CD8 π arm of the cellular immune
The Road to Tumor Immunity system to respond to intracellular pathogens not present in APCs, however, it is necessary that APCs be capable of diverting potential antigens into the class I antigen-processing pathway. With due respect to the immunological consequences of CD8 π T-cell activation, it is presumed that cross-presentation is to some degree selective, and for that reason, primarily a receptor-mediated process. The relevant receptors function, then, by selecting components present in the extracellular space and directing them to the class I antigen-processing pathway. Thus, we have a beginning to a story, in which chaperones complex with an array of tumor-specific immunogenic peptides, and an end to a story, in which an immune response is elicited, and tumor tissue eliminated. What lies between is now coming under higher scrutiny.
Matters Beyond the Tumor
GRP94 was discovered to function as a tumor rejection antigen by Srivastava et al. (2) . In these experiments, GRP94, derived from a panel of independently generated murine chemical sarcomas, demonstrated substantial prophylactic vaccine activity (2) . Importantly, the effect was tumor specific and thus, in the MethA chemical carcinogenesis model, GRP94 isolates from multiple independent tumors, generated in syngeneic hosts, were only effective against the parent tumor; cross-protection was not observed (2) . This observation is critical and is relevant to ongoing arguments regarding the immunological identities of tumor tissue. From these observations, the proposal was made that GRP94 was bound to a tumor-specific array of immunogenic peptides and, importantly, that each tumor was immunologically unique (2, 15) . This proposal was extended and generalized in the proposition that GRP94 binds the entire antigenic peptide repertoire of the cell (16) .
The paradigm of chaperones as tumor rejection antigens includes Hsp90, Hsp70, and calreticulin (5, 6, 8, 10, 15) . Interestingly, not all chaperones are equally or, for that matter, at all immunogenic. Members of the hsp90 chaperone family are most effective, whereas no activity has been attributed to BiP or PDI, though both proteins are well established to function as peptide-binding proteins (7, 8, (17) (18) (19) (20) . This variation in immunological activity has largely been attributed to the differing peptide sequence motifs that each chaperone presumably binds. We are left to consider, though, the molecular basis for the unique and altogether extraordinary capacity of GRP94 to apparently recognize and bind, with high affinity, the entire antigenic peptide repertoire of the cell. Nonetheless, the results of animal model studies of the tumor-specific immunogenicity of GRP94 are indeed impressive. In particular, Tamura and coworkers found GRP94 to display both prophylactic and therapeutic activity in a number of prominent murine tumor models (3) . Interestingly, they observed that GRP94 derived from heterologous normal tissue was also effective at slowing or halting tumor progression, though significantly less so (3). That antitumor activity was observed at all in GRP94 derived from nontumor tissue is itself a topic worthy of further study, and may relate to the peptide-independent immunological qualities of these proteins. Illustrating the significance of these findings, particularly from the standpoint of human health, GRP94 is currently under examination in Phase III clinical trials as an immunotherapy for renal carcinoma.
There is more to GRP94 than meets the (poly)peptide-binding eye. Recently, GRP94, as well as other chaperones, has been shown to induce the maturation and activation of dendritic cells, both in vivo and in vitro (21) (22) (23) . Thus, GRP94, Hsp90 and Hsp70, in a manner independent of their associated peptide repertoire, elicit the up-regulation of a number of immunologically important APC cell-surface molecules, including CD86 and MHC class II, and to stimulate the production and release of cytokines, including TNF-a, IL1-b and IL-12 (21) (22) (23) . These findings suggest that chaperones can significantly influence antigen-independent elements of the cellular immune response and so it is likely, if not highly probable, that such effects contribute significantly to the creation of a tumor microenvironment appropriate for immunological recognition.
Chaperones as Vehicles for Peptide Trafficking
The immunological function of chaperones that has been the greatest focus of attention thus far is their ability to direct associated (poly)peptides into the class I antigen presentation pathway of APCs. Indeed, Udono et al. reported that inactivation of macrophages or CD8 π T cells, with carageenan or CD8 π T-cell-specific monoclonal antibodies, respectively, abrogated the immunogenic activity of GRP94 (1). These findings are of clear significance to the field of vaccine design, and have stimulated investigations into additional, potentially physiological, roles of GRP94 in the regulation of cellular immune responses. One scenario of considerable recent interest concerns the immunological response to cell death. Extending from reports by the Matzinger and Bhardwaj laboratories that necrotic cell extracts can stimulate APC activation and maturation (24, 25) , recent research has explored a role for chaperones in the immunological response to cell death. Two recent studies have reported that necrotic, but not apoptotic, cell death is accompanied by the release of chaperones into the extracellular milieu, thus opening the potential for chaperone-dependent triggering of tissue-directed immune responses (22, 26) . In addition, virally induced cell lysis has been shown to elicit chaperone release, further supporting the hypothesis that the release of chaperone proteins, as occurs in response to pathological cell death, may contribute to the immunological response to pathological injury (26) . However, the physiological relevance of these findings should be critically evaluated; TAP-negative cells, deficient in the transport of peptides into the ER (and thus presumably deficient for peptide loading onto GRP94 and calreticulin), can function in an established animal model for cross-presentation (27, 28) .
The Beginning of the Road: Receptor Mediated Uptake in APCs
How are chaperones recognized by APCs? As originally proposed by Srivastava, APCs bear cell-surface receptors that function in chaperone internalization (29) . Importantly, a number of groups have now demonstrated that receptor-mediated uptake is required for the cross-presentation of chaperone-associated peptides on class I molecules (10, 11) . Though the existence of APC chaperone receptors has been acknowledged for several years, only recently have candidate receptors been isolated and their function in chaperoneelicited immune responses analyzed. In these studies, two broad classes of receptor function have been identified: those that elicit APC activation and those that function in chaperone internalization. Regarding the former, Hsp60, a chaperone unlikely to be complexed with peptides, was shown to signal through the cell-surface receptors CD14 and Tlr-4, whereas GRP94 was shown to activate the NF-kB pathway by an as yet unknown receptor (22, 30, 31) . And with regard to the latter, a series of recent reports have provided evidence identifying CD91 (LRP, a 2 -macroglobulin receptor) as the sole GRP94 internalization receptor (12, 32, 33) . First identified as a GRP94 receptor by affinity chromatography and label-transfer cross-linking strategies, the functional evidence for a direct GRP94 uptake function for CD91 lies in the ability of either CD91-directed antibodies or CD91 ligands to ameliorate re-presentation of GRP94-associated peptides (12) .
CD91 is expressed on a diverse array of cell types, including hepatocytes and fibroblasts, and is known to function in plasma protein clearance, principally that of a 2 -macroglobulin. Because CD91 expression is not APC-restricted, it is important that models of CD91 action in cross-presentation reconcile the postulated immunological function of CD91 with its known serum protein clearance activity. To this end, Binder et al. have hypothesized that CD91 could be readily bifunctional; in the presence of serum, CD91's chaperone-binding activity would be inhibited, whereas in tissues external to the vasculature, CD91 would function in chaperone uptake (12) . In a more recent study, the Srivastava laboratory has reported that CD91 serves as the common chaperone receptor, and thus that multiple chaperone proteins, including GRP94, Hsp90, Hsp70 and calreticulin, utilize CD91 to access the class I antigen processing pathway of APCs (32) .
These landmark studies from the Srivastava laboratory support an immunological role for CD91, particularly in their demonstration that CD91 serum ligands and/or CD91 antibodies inhibit chaperone-dependent re-presentation. These studies also raise a number of interesting questions regarding the internalization and subcellular trafficking pathways of chaperones internalized via CD91. A principal question is one of rec-
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Traffic 2001; 2: 690-697 ognition. If the competition data can be interpreted to indicate that chaperones compete for a common binding site(s) on CD91, then it can be predicted that the diverse array of CD91 chaperone ligands (Hsp90, Hsp70, GRP94, calreticulin) would share either a common sequence or a common tertiary CD91 binding fold. Such a model endows CD91 with properties expected of a receptor functioning in the innate immunity arm of the immune system, in that it would recognize a common structural motif shared by a diverse array of ligands. Alternatively, the competition observed between different chaperones for access to CD91 may reflect allosteric regulation of multiple, distinct and chaperone-specific binding sites. In this model, the binding of a given chaperone to CD91 would negatively influence the binding at a distinct site(s) of other chaperones. Clearly, further studies on the structural basis for chaperone binding to CD91, as well as the tissue-specific basis for the regulation of CD91 function, are necessary to fully define the physiological contribution of CD91 to chaperone-dependent immune responses.
The Heart of the Matter: Where to From Here?
Following endocytosis, the internalized chaperone/peptide complex must traffic to a subcellular compartment competent to engage the peptide in the class I cross-presentation pathway. In broad terms, multiple trafficking pathways can be considered. As depicted in Figure 1 , receptor internalized chaperone proteins could engage two primary pathways. In one pathway, ER chaperones could traffic to the trans-Golgi network, whereupon they would engage the KDEL receptor and traffic in a retrograde manner to the endoplasmic reticulum, the site of peptide loading onto nascent class I molecules. Arguing against this pathway, recent data from our laboratory indicate that Hsp90, which lacks a KDEL motif, and GRP94 which as a resident ER lumenal chaperone bears a KDEL motif, traffic identically in APCs (Berwin, B. and Nicchitta, C.V., unpublished observations). In a second pathway, GRP94 would traffic to an endosomal compartment, whereupon peptide release would occur, with the free peptides then being trafficked to the ER. Both models assume that chaperone-derived peptides load onto nascent class I molecules present in the ER, though no data are currently available to support this assumption.
GRP94 internalized via receptor-mediated endocytosis can be identified in clathrin-coated vesicles and is excluded from a lysosomal-targeted trafficking pathway at trafficking periods of up to 1 h (13, 34) . In contrast, GRP94 internalized via fluid-phase uptake is rapidly degraded (Berwin, B. and Nicchitta, C.V., unpublished observations). These data indicate that the dominant trafficking signals for GRP94 are provided by the chaperone-internalization receptor complex, a conclusion consistent with the observation that GRP94 and Hsp90 display similar subcellular trafficking patterns (Berwin, B. and Nicchitta, C.V., unpublished observations), and suggest that receptor association protects GRP94 from premaThe Road to Tumor Immunity From this compartment, the GRP94-peptide complex could undergo vesicle-mediated transport to the trans-Golgi network, whereupon it would be recognized by the KDEL receptor and undergo retrograde transport to the endoplasmic reticulum (ER). Within the ER, GRP94-associated peptides could be transferred to MHC class I molecules. Alternatively, the GRP94-peptide complex and/or its bound peptide complement could gain access to the cytosol and the peptides could then be transported into the lumen of the endoplasmic reticulum via the TAP transporter, for loading onto MHC class I molecules.
ture proteolysis. In this state, GRP94 traffics to a secondary, perinuclear endosome reminiscent of the Rab11 positive recycling endosome prominent in polarized cells (Berwin, B. and Nicchitta, C.V., unpublished observations) (35, 36) . Though class I molecules can serve as an ultimate destination of the GRP94 associated peptides, the transfer route of peptide from endosomal compartment (s) is not yet clear. Two general hypotheses that address this latter stage are: (i) peptides traffic from an endosome to the ER, likely via the cytosol and the TAP peptide transporter, to bind nascent MHC class-I molecules in the ER; and/or (ii) peptides exchange onto recycling class I molecules in an endosomal compartment. These models are illustrated in Figure 2 and, indeed, there is preliminary evidence for both routes. For example, studies employing APCs derived from TAP -/-mice indicate that TAP is required for cross-presentation of at least some chaperone-associated peptides, suggesting the existence of a cytosolic route for peptide transfer from the endosome to the ER (10, 32) . This conclusion is consist-693 Traffic 2001; 2: 690-697 ent with the 'chaperone relay' hypothesis, proposed by Srivastava and illustrated in Figure 3 (29) . In this hypothesis, peptides derived from internalized GRP94 are transferred via a cytosolic chaperone shuttle to the TAP transporter, for subsequent loading onto nascent class I molecules. In this model, however, it is not readily apparent how GRP94 gains access to the cytosol, how the peptide-bearing population of GRP94 is targeted to or by cytosolic chaperones for direct peptide transfer, nor how the recipient chaperone is then targeted to TAP, for directed peptide transfer to the ER. Alternatively, and as recently reported by several groups, cross-presentation can occur in a TAP-independent manner via an endosomal peptide exchange process (37) (38) (39) . A likely trafficking itinerary for TAP-independent crosspresentation is depicted in Figure 2 and requires that the chaperone/peptide complex traffic to an endosomal compartment containing class I molecules, with peptide exchange occurring within that compartment. In support of this model, Gromme et al. recently reported that endosomal Hypothetical pathway for peptide transfer from GRP94 to MHC class I. GRP94-peptide complexes are depicted as being internalized via a chaperone recognition receptor and trafficking, presumably through an endosomal network, to a compartment accessed by recycling MHC class I molecules. In that compartment, as yet to be identified, a low pH environment would support peptide release and exchange from GRP94 to recycling MHC class I molecules. Peptide transfer might also occur as a consequence of proteolytic degradation of GRP94, the subsequent release of bound peptides, and the transfer of such peptides to recycling MHC class I molecules. MHC class I molecules, bearing the GRP94-derived peptides would then recycle to the cell surface for presentation to CD8 π T cells. Importantly, in this proposed pathway the transfer of GRP94-bound peptides would occur onto mature MHC class I molecules and would not utilize the ER peptide transport or class I peptide-loading machinery.
pH levels are sufficiently acidic to promote the release of peptides from recycling class I complexes, and hypothesize that higher affinity peptides could compete for binding to peptide-free mature class I molecules for subsequent representation at the cell surface (39) . Complementary to this finding, Kleijmeer et al. reported TAP-independent peptide re-presentation and, utilizing ultrastructural analyses, demonstrated that exogenous peptides and class I molecules colocalize to endosomal compartments (37) . To determine whether such a TAP-independent re-presentation pathway functions in GRP94 processing, further work needs to be done to determine whether GRP94/peptide complexes are transported to an endosomal compartment that supports peptide release, whether such a compartment contains class I molecules and, finally, whether peptides can be transferred from GRP94 to mature class I molecules.
In overview description, the endosomal-based chaperone representation pathway bears some similarities to the MHC Traffic 2001; 2: 690-697 class II antigen processing pathway, in that the recipient peptide-binding protein (class I or class II molecule) is trafficked to a site other then the ER to receive its peptide cargo. For class II molecules, the peptide-loading process is tightly regulated and requires accessory factors (DM) that function to allow the incoming peptide to gain access to the class II peptide binding site [reviewed in (40) ]. For class I, the current data suggest that peptide release from class I molecules can occur at conditions of sufficiently low pH (39) . It is also possible that peptide release from GRP94 occurs at similarly reduced pH levels, and so the exchange process becomes one in which acidic conditions serve as the primary regulatory control. As mechanisms go, this is not a particularly satisfying one. It asks that a peptide bind to one site (GRP94) in a reversible, low pH-sensitive manner and yet upon release, associate with a distinct peptide-binding site (class I), and in at least a relatively pH-insensitive manner. Alternatively, we suggest that (poly)peptide release from GRP94 could occur in an endosomal compartment via a proteolytic event, with
The Road to Tumor Immunity (29) , GRP94-peptide complexes are internalized via a receptor-mediated pathway and from an internal compartment, the peptide component is transported to the cytosol. In the cytosol the GRP94-derived peptides then re-complex with cytosolic chaperones, such as Hsp90 and Hsp70, and are directed to TAP, wherein they are translocated into the lumen of the endoplasmic reticulum for loading onto nascent MHC class I molecules. In this hypothetical pathway, the peptides derived from internalized GRP94 are re-presented in concert with the biogenesis and transport of newly synthesized class I molecules. the product peptides then undergoing selection by recycling empty-state mature class I molecules for re-presentation at the cell surface.
Concluding Thoughts
Much has been learned in the past few years regarding chaperone-based antigen re-presentation, yet much remains to be explored and defined. The recent report of CD91 as the unique receptor mediating chaperone endocytosis and trafficking is very intriguing, particularly in that ligation of CD91 has been demonstrated to affect re-presentation, a physiological endpoint. Future experiments, in which CD91 is ectopically expressed in CD91-negative cell lines and the binding, uptake and trafficking of chaperones are examined will prove useful in developing insights into CD91 function. It is through this approach, for example, that Avramoglu et al. established a CD91 function in a 2 -macroglobulin uptake (41) . In addition to identification of a chaperone receptor, knowledge of mechanisms and patterns of chaperone trafficking within APCs has incrementally increased. Receptor-mediated endocytosis of chaperones into coated vesicles, originally reported by Arnold-Schild et al. (34) , has now evolved into chaperones trafficking to sequential subclasses of endosomes, but not to lysosomes. Additionally, receptor-mediated endocytosis has been shown to be required for chaperone-associated peptide re-presentation, suggesting a critical role for the chaperone receptor(s) in trafficking the associated peptides to endosomes involved in the re-presentation pathway. Thus, future studies will likely be directed at identifying the subcellular site(s) and mechanism of peptide release from the chaperone, as well as the pathway(s) peptides take to reach, and be bound by, MHC class I molecules. Such studies would address questions regarding chaperone/peptide trafficking, and would also answer pressing questions regarding crosspresentation in general. The observation that chaperones, independent of bound peptide, can elicit cytokine responses from APCs is also of great interest. Such studies raise the question of the role that local inflammatory responses play in tumor rejection, either independently or as a cofactor to CD8 π peptide-specific responses.
